Argenica Therapeutics (ASX:AGN) has released promising data from its Phase 2 clinical trial of ARG-007, a neuroprotective peptide designed to…
Recce Pharmaceuticals (ASX:RCE) has commenced patient dosing in its registrational Phase 3 trial for diabetic foot infections in Indonesia, one of the largest such studies globally.
Emyria authorised to prescribe MDMA to treat Australian’s with PTSD.
Paradigm Biopharmaceutical will feature their injectable PPS for treating osteoarthritis and mucopolysaccharidosis at international conferences.
A swift recruitment process for its trial escalation shows high demand for better and more accessible prostate cancer therapy.
Firebrick Pharma research has indicated the efficacy of its nasal spray in treating symptoms associated with the common cold.
MGC Pharmaceuticals shows encouraging signs for cannabinoid-based COVID treatment.